This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

Bruker Corporation
11/4/2026
Good morning, everyone, and welcome to the Bruker Corporation third quarter 2026 earnings conference call. All participants will be in a listen-only mode. Should you need assistance, please see a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star and then one on your touch-tone phones. To withdraw your questions, you may press star and two. Please also note today's event is being recorded. At this time, I'd like to turn the floor over to Joe Koska, Director of Investor Relations. Please go ahead.
Good morning. I would like to welcome everyone to Bruker Corporation's third quarter 2026 earnings conference call. My name is Joe Koska, and I'm the Director of Bruker Investor Relations. Joining me on today's call are our President and CEO, Frank Laukien, and our EVP and CFO, Gerald Herman. In addition to the earnings release we issued earlier today, during today's conference call, we will be referencing a slide presentation that can be downloaded from the events and presentations section of Bruker's investor relations website. During today's call, we will be highlighting non-GAAP financial information. Reconciliations of our non-GAAP to GAAP financial measures are included in our earnings release and are posted on our website at ir.bruker.com. Before we begin, I would like to reference Bruker's safe harbor statement, which is shown on slide two of the presentation. During this conference call, we will or may make forward-looking statements regarding future events and the financial and operational performance of the company that involve risks and uncertainties, including those related to our recent acquisitions, geopolitical risks, wars or blockades, market demand, tariffs, currency exchange rates, competitive dynamics, or supply chains. The company's actual results may differ materially from such statements. Factors that might cause such differences include, but are not limited to, those discussed in today's earnings release and in our Form 10-K for the period ending December 31, 2025, as updated by our other SEC filings, which are available on our website and on the SEC's website. Also, please note that the following information is based on current business conditions and on our outlook as of today, November 4th, 2026. We do not intend to update our forward-looking statements based on new information, future events, or for other reasons, except as may be required by law prior to the release of our fourth quarter and full year 2026 financial results expected in February 2026. You should not rely on these forward-looking statements as necessarily representing our views or outlook as of any date after today. We will begin today's call with Frank providing an overview of our business progress. Gerald will then cover the financials for the third quarter of 2026 in more detail and comment on our full year 2026 financial outlook.
Now, I'd like to turn the call over to Bruker CEO, Frank Laukien. Thank you Joe. Good morning everyone and thank you for joining us on today's third quarter 26 earnings call. Bruker continues to drive significant advances in post-genomic disease biology solutions and drug discovery from proteoforms to glycobiology and from functional protein interactions to spatial biology. These foundational advances in disease biology together with strong growth drivers in specialty infectious disease diagnostics and in our deep tech and semiconductor metrology franchise are expected to lead to significant revenue growth, acceleration, and further margin expansion. Brooker's positive bookings trends continued in the fifth consecutive quarter of Brooker Scientific Instruments, or BSI, book-to-bill greater than one, as we see increasing strength in most of our end markets, and I will highlight three areas in particular. First, U.S. academic and government, or ACAGOV, In the third quarter, our BSI organic bookings in the US ECHA GOV market grew in the double-digit percentage year-over-year. This was the first quarter with year-over-year bookings growth in US ECHA GOV since the NIH funding disruption in 2025. The prior year comparison was a weak one, but this is nonetheless encouraging. And by the way, we also expect year-over-year organic bookings growth in U.S. Accagov in the fourth quarter. One could speculate that last night's blue wave in the midterms could also bode well for U.S. Accagov funding in fiscal 27 and beyond. Second, China. BSI organic bookings in China were up over 20% both in the third quarter and year-to-date. This consists of broad-based demand strength as almost all of our BSI end market orders in China grew nicely. Third, year-to-date we've seen greater than 30% organic bookings growth in BSI Semicon Metrology markets in the quarter. This robust order growth is being fueled by the AI megatrend, which requires our metrology solutions for logic, chip boundaries, high bandwidth memory, and advanced packaging. While the lead times on these orders are longer than most of our life science tools, we expect to see these semi-orders convert into revenue, mostly in fiscal year 27 and some in fiscal year 28. Speaking of artificial intelligence, Speaking of AI, artificial intelligence, in August, we started a strategic collaboration with and we did a minority investment in Attenari Technologies, a pioneer of self-driving labs and agentic AI-driven chemistry R&D. Attenari integrates our ChemSpeed lab automation and Bruker analytical measurement instruments into its agentic AI workflows. The Attenary Lab in Boston includes ChemSpeed Robotics and Bruker Benchtop NMR for small molecule synthesis and catalysis in pharmaceutical R&D and process development. All right, let's dive into the numbers. Let's turn to slide four now. For the P&L performance in the third quarter, where we achieved significant margin expansion and non-GAAP EPS growth, driven by our focus on cost discipline and execution. Our third quarter 26 reported revenues of $874 million increased 1.6% year-over-year with organic growth of 0.7%. Our third quarter 26 non-GAAP growth and operating margins were 51.3% and 16.3% respectively, both up significantly year-over-year. Our Q3 26 diluted non-GAAP EPS was 56 cents, up 24% from Q3 25. Moving to slide five, our year to date nine months Q3 26 revenues increased by 3.1% to 2.54 billion with organic revenue essentially flat. Our year to date, Non-GAAP gross margin, operating margin, and EPS were all up nicely year-over-year, and their year-to-date performance is summarized on slide five. As Gerald will explain in more detail shortly, in Q3 and year-to-date, our free cash flow also has improved considerably, and we have made excellent progress with deleveraging. Please turn to slides 6 and 7 now, where we highlight the year-to-date third quarter performance of our now reorganized three scientific instruments groups and of our best segment, all on a constant currency or CER and year-over-year basis. Year-to-date, the biosystems group revenue was $1.2 billion, up low single digits percentage year-over-year in CER. Strength in biopharma and translational research was partially offset by weakness in ECHAGOV. Biosystems saw strong CER growth in IR Raman spectroscopy and in mass spectrometry, driven in part by the top work acquisition, which was partially offset by softness in NMR. Year to date, 2026, our new or newly elevated microbiology and infection diagnostics group had revenues of 396 million which increased in the low single digits percentage driven primarily by robust molecular diagnostics revenue growth. Turning to slide seven. Year-to-date Bruker Nano revenue was $770 million with a low single-digit percentage CER decline. Robust year-to-date growth in semi-metrology and biopharma was offset by weakness in AgaGov and industrial. Semi-revenues were down double digits in the third quarter, primarily driven by our previously communicated push-outs of semi-metrology instruments from the third quarter. We had been very explicit about that in our Q2 earnings call when Gerald gave Q4 color that we expected the 20 million push out from Q3 in semi-convectrology. Finally, year to date, best revenues were up 8.3% in CER, Net-Up Intercompany Eliminations, with strong growth in research instruments, or RI, and solid growth also in superconductors. Right. Moving to slide eight, we highlight our recent acquisition of Mimetas, a leading humanized organ on a chip or NAM platform. NAM stands for New Approach Methodology. It's a commonly used term in the industry and also by the FDA. I'll let you read some of the background on Mimetas. I think it's a reading slide rather than me going through every bullet. but I think it is very important to get the higher level perspective that in addition to multiomics and spatial and structural biology and AI augmented drug discovery, one of the pain points and one of the reasons for the failure rates of so many drugs when promising drugs gets translated from mouse models or animal models to humans are toxicities, are off-target toxicities that are unique to humanized models and human physiology. And Mimetas with its humanized organs on a chip, which can be nicely automated, which have many disease models and are poised for very significant double-digit growth with high gross margins, we think are probably the best type of systems of this type on the market which is why after extensive research on that market we acquired a majority in Mimetas. We're very excited and we think this will complement our multi-omic spatial biology, structural biology in drug discovery in particular drug discovery and development in a very important way. It's a high priority for just about every biopharma company. Right. On slide nine, we touch on a few recent advances in functional proteomics with novel workflows for drug discovery and disease biology launched at the recent International UPO Conference in Singapore. Again, I will not read every bullet, but we had very significant further advances in this multi-DIAM method on our TIMS Ultra for bottom-up proteomics. for plasma proteomics, single-cell proteomics, where we see in that net more peptides and protein groups and also more isoforms, sequence variants, and all the other things that traditional MS-based methods or the affinity methods simply cannot see, but they're functionally very important for better AI frontier models or better drug discovery. On the right-hand side, our team's OMNI continues to be very focused a very successful system in the market with significant orders and here are new workflows that are really very very important one in glycobiology where with our unique trapped electron-based fragmentation I won't go into technical details but it's really crucial to do this at scale at speed and in very sensitive manners and glycobiology is tremendously important but has been traditionally very difficult to study Moreover, oligonucleotides and native RNA analysis is another important area whether mRNA is a drug target or a potential drug, a potential RNA drug and the instrument can perform outstanding workflows now in this area as well. We think this bodes well for further rapid adoption in academic medical centers which have good funding as well as in Pharma companies and biotech companies. All right, that about does it for me. In summary, the third quarter we achieved significant margin expansion and non-GAAP EPS growth and our positive booking trends continued. Our BSI organic bookings and BSI backlog are both up mid single digits percentage year to date. This helps de-risk our fourth quarter and sets us up for meaningful, further performance improvements and growth acceleration in fiscal year 27 and beyond. Let me turn the call over to our CFO, Gerald.
You're reading a preview of the BRKR Q3 2026 earnings call.
Free account.
Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.
Use this data in your own app
Pull this call's transcript, audio and slides with the Earnings call transcripts API.
See pricing